Skip to main content
NewslettersWatchlist

Medipharm Labs Corp(LABS-T)
TSX

Today's Change
Real-Time Last Update
Day Low0.0800
Day High0.0850
Open:0.0800
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Automated Summaries - The Globe and Mail
Closing Bell: Medipharm Labs Corp flat on Thursday (LABS)
Newswire.ca
MediPharm Labs Provides Conference Call Recording Details
Newswire.ca
MediPharm Labs Reports Fourth Quarter and Full Year Results
Baystreet
Stocks in play: MediPharm Labs Corp.
Newswire.ca
MediPharm Labs Provides Update on German Cannabis Legalization
Newswire.ca
MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2023 Financial Results
AI-generated - The Globe and Mail
MediPharm Labs: Top 10 Undervalued Drug Manufacturers Industry Stocks (LABS)
Baystreet
Stocks in play: MediPharm Labs Corp.
Newswire.ca
MediPharm Labs Achieves Pharmaceutical GMP Certification with Brazilian Health Authority
AI-generated - The Globe and Mail
MediPharm Labs: Top 10 Undervalued Healthcare Sector Stocks on TSX (LABS)
Baystreet
Stocks in play: MediPharm Labs Corp.
Newswire.ca
MediPharm Labs Provides Update on Board of Directors and Long Term Incentive Program
AI-generated - The Globe and Mail
MediPharm Labs: Top 10 Undervalued Healthcare Sector Stocks on TSX (LABS)
Newswire.ca
MediPharm Labs Reports Third Quarter Results
Newswire.ca
MediPharm Labs Sets Date to Report Third Quarter 2023 Financial Results
Baystreet
Stocks in play: MediPharm Labs Corp.
Newswire.ca
MediPharm Labs Update on $9M Settlement Agreement - All Tilray Shares Sold and Converted to Cash
Baystreet
Stocks in play: MediPharm Labs Corp.
PR Newswire
MediPharm Labs Settles an Outstanding Claim for $9M
Baystreet
Stocks in play: MediPharm Labs Corp.
PR Newswire
MediPharm Labs Improves Domestic Sales Gross Margin with Termination of Shelter Cannabis Brands Royalty Agreement
PR Newswire
MediPharm Labs Completes Sale of Vacant Land for Cash Proceeds of $1.9 million
PR Newswire
MediPharm Labs Publishes Study Investigating Medical Cannabis Impacts on Anxiety and Depression Outcomes in Fibromyalgia Patients
Newswire.ca
MediPharm Labs Reports Second Quarter Results with Doubling of Revenue and Record Margin Growth
PR Newswire
MediPharm Labs Sets Date to Report Second Quarter 2023 Financial Results
Baystreet
Stocks in play: MediPharm Labs Corp.
PR Newswire
MediPharm Labs Makes First Delivery of Cannabis Clinical Trial Material to US Research Partner and Provides Update on US FDA Status
PR Newswire
MediPharm Labs Announces Voting Results From the 2023 Annual Meeting of Shareholders
Newswire.ca
MediPharm Labs Announces Change of Auditor
Newswire.ca
MediPharm Labs Reports First Quarter Results with Growth in Sales, Margin and EBITDA
Newswire.ca
MediPharm Labs Sets Date to Report First Quarter 2023 Financial Results
Baystreet
Stocks in play: MediPharm Labs Corp.

Profile

MediPharm Labs Corp is a pharmaceutical company specializing in precision-based cannabinoids. The Company operates in one reportable segment, the production and sales of cannabis flower, extracts, and derivative products. Through its wholesale and white-label platforms, MediPharm Labs formulates, develops, processes, packages, and distributes cannabis extracts and cannabinoid-based products to domestic and international markets. Geographically the company has a presence in Canada, Australia, Germany, and other countries and the majority of revenue derives from Canada.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.